Le produit a bien été ajouté au panier.

discount label
H-KSPWFTTL-OH
Vue en 3D

Biosynth logo

H-KSPWFTTL-OH

Ref. 3D-PP44136

1mg
202,00 €
10mg
234,00 €
100mg
412,00 €
Livraison estimée en/au États-Unis, le vendredi 27 décembre 2024

Informations sur le produit

Nom :
H-KSPWFTTL-OH
Synonymes :
  • NH2-Lys-Ser-Pro-Trp-Phe-Thr-Thr-Leu-OH
Description :

Peptide H-KSPWFTTL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-KSPWFTTL-OH include the following: Cytotoxic T lymphocytes to endogenous mouse retroviruses and mechanisms of retroviral escape WR Green - Immunological reviews, 1999 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-065X.1999.tb01298.x The role of proximal and distal sequence variations in the presentation of an immunodominant CTL epitope encoded by the ecotropic AK7 MuLV V Kim, WR Green - Virology, 1997 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S004268229798747X A single amino acid variation within an immunodominant AKR/Gross MuLV cytotoxic T-lymphocyte epitope leads to a loss in immunogenicity V KIM, WR GREEN - Viral Immunology, 1998 - liebertpub.comhttps://www.liebertpub.com/doi/abs/10.1089/vim.1998.11.197 Naturally occurring TAP-dependent specific T-cell tolerance for a variant of an immunodominant retroviral cytotoxic T-lymphocyte epitope V Kim, JW Yewdell , WR Green - Journal of Virology, 2000 - Am Soc Microbiolhttps://journals.asm.org/doi/abs/10.1128/jvi.74.8.3924-3928.2000 Cytolytic T lymphocyte responses to AKR/gross murine leukemia virus induced tumors V Kim - 1999 - search.proquest.comhttps://search.proquest.com/openview/ccc7f748a4261aa7ffc90fa75060d4ea/1?pq-origsite=gscholar&cbl=18750&diss=y Identification of Enhanced Vaccine Mimotopes for the p15E Murine Cancer Antigen S Zhou , Y Song , Y Luo , B Quinn, Y Jiao, MD Long - Cancer Research , 2024 - AACRhttps://aacrjournals.org/cancerrescommun/article/4/4/958/742832 Apoptosis of epitope-specific antiretroviral cytotoxic T lymphocytes via Fas ligand-Fas interactions RF Rich, WR Green - Viral Immunology, 2006 - liebertpub.comhttps://www.liebertpub.com/doi/abs/10.1089/vim.2006.19.424 Characterization of the Fas ligand/Fas-dependent apoptosis of antiretroviral, class I MHC tetramer-defined, CD8+ CTL by in vivo retrovirus-infected cells RF Rich, WR Green - The Journal of Immunology, 2002 - journals.aai.orghttps://journals.aai.org/jimmunol/article/168/6/2751/34719 Spontaneous in vivo retrovirus-infected T and B cells, but not dendritic cells, mediate antigen-specific Fas ligand/Fas-dependent apoptosis of anti-retroviral RF Rich, WJ Cook, WR Green - Virology, 2006 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0042682205006574 Double-cleavage production of the CTL epitope by proteasomes and PA28: role of the flanking region N Shimbara, H Nakajima, N Tanahashi - Genes to , 1997 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2443.1997.1610359.x Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes MPM Vierboom , HW Nijman , R Offringa - The Journal of , 1997 - rupress.orghttps://rupress.org/jem/article-abstract/186/5/695/7269 Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity MCW Feltkamp , MPM Vierboom , WM Kast - Molecular , 1994 - Elsevierhttps://www.sciencedirect.com/science/article/pii/0161589094901554 Recognition of endogenous ecotropic murine leukaemia viruses by anti-AKR/Gross virus cytotoxic T lymphocytes (CTL): epitope variation in a CTL-resistant virus MA Coppola , TM Lam - Journal of general , 1995 - microbiologyresearch.orghttps://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-76-3-635 Cytotoxic T lymphocyte epitopes of HIV-1 Nef: generation of multiple definitive major histocompatibility complex class I ligands by proteasomes M Lucchiari-Hartz, PM Van Endert , G Lauvau - The Journal of , 2000 - rupress.orghttps://rupress.org/jem/article-abstract/191/2/239/50980 NK cell transfer overcomes resistance to PD-(L) 1 therapy in aged mice J Hou, S Xie, J Gao, T Jiang, E Zhu, X Yang - Hematology & Oncology, 2024 - Springerhttps://link.springer.com/article/10.1186/s40164-024-00511-9 Intratumoral injection of interferon-alpha and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy J Dubrot, A Palazon , C Alfaro - journal of cancer, 2011 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.25333 Wnt3a neutralization enhances T-cell responses through indirect mechanisms and restrains tumor growth I Pacella, I Cammarata, C Focaccetti, S Miacci - Cancer Immunology , 2018 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/6/8/953/469079 Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12 I Melero, JI Quetglas, M Reboredo, J Dubrot - Cancer research, 2015 - AACRhttps://aacrjournals.org/cancerres/article-abstract/75/3/497/606515 High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy HJ Zeh , D Perry-Lalley, ME Dudley - The Journal of , 1999 - journals.aai.orghttps://journals.aai.org/jimmunol/article/162/2/989/31612 An immunodominant Kb-restricted peptide from the p15E transmembrane protein of endogenous ecotropic murine leukemia virus (MuLV) AKR623 that restores HD White , DA Roeder, WR Green - Journal of virology, 1994 - Am Soc Microbiolhttps://journals.asm.org/doi/abs/10.1128/jvi.68.2.897-904.1994 Integrating CD4+ T cell help for therapeutic cancer vaccination in a preclinical head and neck cancer model H Shibata, N Xu, S Saito, L Zhou , I Ozgenc - , 2021 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/2162402X.2021.1958589 A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation F Ossendorp , M Eggers, A Neisig, T Ruppert - Immunity, 1996 - cell.comhttps://www.cell.com/trends/immunology/fulltext/S1074-7613(00)80488-4 Enhanced tumor control with combination mTOR and PD-L1 inhibition in syngeneic oral cavity cancers EC Moore, HA Cash, AM Caruso, R Uppaluri - Cancer immunology , 2016 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/4/7/611/468556 Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy C He , X Duan , N Guo, C Chan, C Poon - Nature , 2016 - nature.comhttps://www.nature.com/articles/ncomms12499 Immunodominant mink cell focus-inducing murine leukemia virus (MuLV)-encoded CTL epitope, identified by its MHC class I-binding motif, explains MuLV-type AJ Sijts , F Ossendorp , EA Mengede - (Baltimore, Md.: 1950 , 1994 - journals.aai.orghttps://journals.aai.org/jimmunol/article-abstract/152/1/106/25902 Chemical conjugate TMV-peptide bivalent fusion vaccines improve cellular immunity and tumor protection AA McCormick, TA Corbo, S Wykoff-Clary - Bioconjugate , 2006 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/bc060124m TMV-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models AA McCormick, TA Corbo, S Wykoff-Clary, LV Nguyen - Vaccine, 2006 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X06007079

Avis:
Nos produits sont destinés uniquement à un usage en laboratoire. Pour tout autre usage, veuillez nous contacter.
Marque:
Biosynth
Stockage à long terme :
Notes :

Propriétés chimiques

MDL:
Point de fusion :
Point d'ébullition :
Point d'éclair :
Densité :
Concentration :
EINECS :
Merck :
Code SH :

Informations sur les risques

Numéro ONU :
EQ:
Classe :
Phrases R :
Phrases S :
Transport aérien interdit :
Informations sur les risques :
Groupe d'emballage :
LQ :

Question d’ordre technique sur : 3D-PP44136 H-KSPWFTTL-OH

Veuillez plutôt utiliser le panier afin de demander un devis ou passer commande

Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages

* Champ obligatoire
Bienvenue chez CymitQuimica !Nous utilisons des cookies pour améliorer votre visite. Nous n’incluons pas de publicité.

Veuillez consulter notre Politique de Cookies pour plus de détails ou ajustez vos préférences dans "Configurer".